Dr. Daniel Pievsky, DO

Dr. Pievsky practices at Yale New Haven Health Westerly Hospital in Westerly, Rhode Island, part of Yale New Haven Health System.

Dr. Pievsky's NPI, 1346669462, was assigned on April 16, 2014. Dr. Pievsky graduated from University of New England, College of Osteo Medicine in 2014. Dr. Pievsky holds Rhode Island license DO01016.

Dr. Pievsky's primary practice is Yale New Haven Health Westerly Hospital, at 25 Wells Street, Westerly, RI 02891 in Washington County. The practice phone is (401) 596-6000.

Dr. Pievsky's primary practice is Yale New Haven Health Westerly Hospital in Westerly, Rhode Island, part of Yale New Haven Health System. Dr. Pievsky is also affiliated with Yale New Haven Hospital. The medical group on file is Northeast Medical Group. Dmand AI also links Dr. Pievsky to 1 more hospital and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Pievsky practices, 4 sites in all. Vendor and product names are available with a free account.

Gastroenterology is Dr. Pievsky's primary specialty in the NPI Registry, under taxonomy code 207RG0100X. Dmand AI has Dr. Pievsky's licenses on file in 3 states: Rhode Island, Connecticut and New Jersey.

CMS data shows 688 Medicare services from Dr. Pievsky across 11 procedure codes in 2024, for 370 Medicare patients. Medicare paid $70,880 for them.

CMS counts 370 Medicare patients who saw Dr. Pievsky in 2024. The largest group is 65 to 74, with 151 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 13% are also on Medicaid. Their average risk score is 1.42, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Pievsky's median patient age at 70, with 46% women.

In 2024, Dr. Pievsky wrote 1,123 Medicare Part D claims for 398 patients. 88% of them were for generic drugs. CMS names the drug for 950 of them, across 18 drugs with 11 or more claims each, at $267,582 in total drug cost. In 2023, CMS named 784 claims across 13 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Pievsky for performance year 2024, reported through an alternative payment model (APM). Dr. Pievsky accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 120 procedures of upper gastrointestinal (gi) endoscopy for acid reflux by Dr. Pievsky, more than 80% of the clinicians it reports for that procedure.

Removal of skin lesions: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 5 papers to Dr. Pievsky, published from 2012 to 2019. 2012 was the busiest year, with 2. The most frequent topics are Cholangiopancreatography, Endoscopic Retrograde. Dr. Pievsky has published most often in Gastrointest Endosc. Dr. Pievsky's most frequent co-authors are Nikolaos T. Pyrsopoulos, MBA, MD, PhD, John Robinson Saltzman, MD and Matthew Alexander Kutner, DO.

CMS Open Payments shows 2 general payments to Dr. Pievsky from 2 drug and device companies from 2016 to 2023. Food and beverage make up the largest share, 100% of the total. Genentech, Inc. paid the most, $125.

Dr. Pievsky graduated from University of New England, College of Osteo Medicine in 2014.